Recursion Pharmaceuticals Inc. (RXRX) News
Filter RXRX News Items
RXRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RXRX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest RXRX News From Around the Web
Below are the latest news stories about RECURSION PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RXRX as an investment opportunity.
Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?The mean of analysts' price targets for Recursion Pharmaceuticals (RXRX) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Recursion Pharmaceuticals price target lowered to $10 from $12 at BofABofA analyst Alec Stranahan lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $10 from $12 and keeps a Neutral rating on the shares. While political and rate uncertainty continues to be an overhang, the firm views the health of the Biopharma sector as “markedly improved from 2022 lows.” For stocks in its coverage, the firm continues to like late-stage clinical or early launch stories, although it sees Phase 1 clinical programs with derisking data and near-term catalysts as “ |
AMD Invests in Drug-Discovery Company Absci in Push to Sell AI ChipsThe $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other industries. |
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & MoreREC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsREC-4539, a potential best-in-class LSD1 inhibitor, is the first designed to be reversible and CNS penetrant for small-cell lung cancerSalt Lake City, UT, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announ |
Is Recursion Pharmaceuticals Stock a Millionaire Maker?Successfully navigating the stock market requires patience and a long-term perspective. Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical-stage biotech that may have that level of potential. The company harnesses artificial intelligence (AI) for drug discovery, promising to revolutionize medicine. |
1 Artificial Intelligence (AI) Stock That Could Soar in 2025Recursion Pharmaceuticals (NASDAQ: RXRX) could be one of them. Let's figure out whether investing in Recursion Pharmaceuticals ahead of 2025 is worth it. Recursion Pharmaceuticals uses AI to speed up the drug discovery and development process. |
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesSalt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that on December 19, 2024, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 7,952,836 shares of its class A common stock in the aggregate to 230 new employees under Recursion's 2024 Indu |
Jim Cramer Says He Was Wrong on NVIDIA Holding Recursion Pharmaceuticals (RXRX)We recently published a list of Jim Cramer’s Latest Calls: Top 10 Stocks. In this article, we are going to take a look at where Recursion Pharmaceuticals Inc (NASDAQ:RXRX) stands against other stocks highlighted in Jim Cramer’s latest calls. Jim Cramer in a recent program talked about Bitcoin and reminded investors that he has always […] |
Recursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early TrialsWe recently compiled a list of the 10 AI News Investors Probably Missed. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against the other AI stocks. As artificial intelligence continues to reshape industries, experts are increasingly focusing on how its integration will impact investment strategies. The growth […] |
Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short SellersWe recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other worst ARK stocks to buy according to short sellers. Cathie Wood of ARK Investment is one of Wall Street’s most well-known hedge […] |